{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T21:23:20Z","timestamp":1787433800411,"version":"build-2736575974"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aohep.2026.102235","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:29:24Z","timestamp":1779676164000},"page":"102235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-2279","authenticated-orcid":false,"given":"Federico","family":"Pi\u00f1ero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102235_bib0001","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0004","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0006","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Josep","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2026.102235_bib0007","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0008","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0009","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2026.102235_bib0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0011","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0012","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0013","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0014","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b\u20132, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0017","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0018","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0019","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0021","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0022","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0024","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2026.102235_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11648","article-title":"European Society of Organ Transplantation (ESOT) Consensus Report on downstaging, bridging and immunotherapy in liver Transplantation for hepatocellular carcinoma","volume":"36","author":"Claasen","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.aohep.2026.102235_bib0026","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0027","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D\u2019Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0028","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","article-title":"Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation","volume":"81","author":"Li","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0029","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0031","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2024.01.018","article-title":"Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice","volume":"80","author":"Cabibbo","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0032","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jhep.2025.07.020","article-title":"Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma","volume":"83","author":"Cabibbo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0033","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0034","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/j.jhep.2024.04.023","article-title":"Evidence and choice: the BCLC vision for tailoring clinical decision-making","volume":"81","author":"Reig","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0035","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0036","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/HEP.0000000000000527","article-title":"Indolent cancer and pattern of progression: two missing parameters in trial design for hepatology","volume":"79","author":"Iavarone","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0037","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/HEP.0000000000001163","article-title":"Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy","volume":"81","author":"Scheiner","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0038","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000536549","article-title":"Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression","volume":"13","author":"Liu","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101781","article-title":"Treatment for hepatocellular carcinoma after immunotherapy","volume":"30","author":"Chan","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0040","unstructured":"Hern\u00e1n M.A., Robins J.M. Causal inference. 2018."},{"key":"10.1016\/j.aohep.2026.102235_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2026.102235_bib0042","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.aohep.2026.102235_bib0043","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in Hepatocellular carcinoma: AASLD Consensus Conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0044","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","article-title":"Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival","volume":"70","author":"Llovet","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.aohep.2026.102235_bib0046","article-title":"Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more","volume":"3","author":"Olivier","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0047","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.aohep.2026.102235_bib0048","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2023.02.022","article-title":"International liver cancer association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance","volume":"79","author":"Singal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0049","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.aohep.2026.102235_bib0050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41416-019-0513-7","article-title":"Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials","volume":"121","author":"Montal","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0051","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0052","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000529996","article-title":"Albumin-bilirubin grade analyses of Atezolizumab plus Bevacizumab versus Sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the phase III IMbrave150 study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0053","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0054","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101110","article-title":"Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC","volume":"28","author":"Pi\u00f1ero","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0056","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","article-title":"Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death","volume":"31","author":"Cabibbo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.aohep.2026.102235_bib0057","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70379","article-title":"Atezolizumab plus Bevacizumab for TACE-unsuitable intermediate-stage HCC beyond up-to-7 criteria: final analysis of REPLACEMENT","volume":"45","author":"Ueshima","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102235_bib0058","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70092","article-title":"Hepatic recompensation before systemic therapy for hepatocellular carcinoma yields comparable survival to compensated cirrhosis","volume":"45","author":"Pi\u00f1ero","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102235_bib0059","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The Baveno VII concept of cirrhosis recompensation","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.aohep.2026.102235_bib0060","doi-asserted-by":"crossref","unstructured":"Qiu P., Sheng J. A two-stage procedure for comparing hazard rate functions. vol. 70. 2007.","DOI":"10.1111\/j.1467-9868.2007.00622.x"},{"key":"10.1016\/j.aohep.2026.102235_bib0061","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/eurheartj\/ehy770","article-title":"Limitations of hazard ratios in clinical trials","volume":"40","author":"Stensrud","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.aohep.2026.102235_bib0062","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/jnci\/djm265","article-title":"Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots","volume":"100","author":"Royston","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.aohep.2026.102235_bib0063","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/sim.4780101208","article-title":"Survival analysis 1982\u20131991: the second decade of the proportional hazards regression model","volume":"10","author":"Andersen","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.aohep.2026.102235_bib0064","unstructured":"Fox J. Cox proportional-hazards regression for survival data. n.d."},{"key":"10.1016\/j.aohep.2026.102235_bib0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01520-0","article-title":"Which test for crossing survival curves? A user\u2019s guideline","volume":"22","author":"Dormuth","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.aohep.2026.102235_bib0066","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0067","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.aohep.2026.102235_bib0068","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0069","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/liv.15502","article-title":"Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: an international observational study","volume":"43","author":"Talbot","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102235_bib0070","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.13988","article-title":"Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse?","volume":"39","author":"M\u00e4hringer-Kunz","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102235_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103350","article-title":"Critical review of oncology clinical trial design under non-proportional hazards","volume":"162","author":"Ananthakrishnan","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.aohep.2026.102235_bib0072","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djae028","article-title":"Association of differential censoring with survival and suboptimal control arms among oncology clinical trials","volume":"116","author":"Hsu","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.aohep.2026.102235_bib0073","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.jacc.2019.08.1034","article-title":"Nonproportional hazards for time-to-event outcomes in clinical trials: JACC review topic of the week","volume":"74","author":"Gregson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.aohep.2026.102235_bib0074","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000525671","article-title":"Atezolizumab plus Bevacizumab versus Sorafenib for unresectable hepatocellular carcinoma: results from older adults enrolled in the IMbrave150 randomized clinical trial","volume":"11","author":"Li","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101185","article-title":"From evidence to clinical practice: bridging the gap of new liver cancer therapies in Latin America","volume":"29","author":"Pi\u00f1ero","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539897","article-title":"Efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular carcinoma with Main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0077","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7025","article-title":"Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma","volume":"13","author":"Kinami","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.aohep.2026.102235_bib0078","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102235_bib0079","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000549955","article-title":"Early safety results from the phase 3b SIERRA study of Durvalumab and Tremelimumab as first-line treatment for participants with unresectable hepatocellular carcinoma and a poor prognosis","author":"Chan","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0081","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0082","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D\u2019Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma\u2014A meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0084","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0085","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0086","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/liv.14436","article-title":"International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis","volume":"40","author":"D\u00edaz-Gonz\u00e1lez","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102235_bib0087","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2026.102235_bib0088","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3390\/cells10092227","article-title":"Immune checkpoint inhibitors in people living with hiv\/aids: facts and controversies","volume":"10","author":"Castelli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.aohep.2026.102235_bib0089","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","article-title":"International liver cancer association (ILCA) White Paper on biomarker development for hepatocellular carcinoma","volume":"160","author":"Singal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102235_bib0090","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to Regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102235_bib0091","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1002\/cncr.25257","article-title":"Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma","volume":"116","author":"Shao","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.aohep.2026.102235_bib0092","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-21-3275","article-title":"Alpha-fetoprotein as a potential surrogate biomarker for Atezolizumab + Bevacizumab treatment of hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.aohep.2026.102235_bib0093","article-title":"Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC","volume":"7","author":"Kohya","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.aohep.2026.102235_bib0094","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.aohep.2026.102235_bib0096","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0097","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/HEP.0000000000001385","article-title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase 3 randomized clinical trial","volume":"83","author":"Lau","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0098","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0099","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma","volume":"5","author":"Scheiner","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.aohep.2026.102235_bib0100","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102235_bib0101","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.aohep.2026.102235_bib0102","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Hoshida","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2026.102235_bib0103","article-title":"Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma","volume":"0","author":"Nault","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102235_bib0104","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102235_bib0105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102235_bib0106","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0107","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular markers of response to Anti-PD1 therapy in advanced hepatocellular carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2026.102235_bib0108","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0109","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0110","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102235_bib0111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41388-020-01519-1","article-title":"Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma","volume":"40","author":"von Felden","year":"2021","journal-title":"Oncogene"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T21:08:50Z","timestamp":1787432930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1665268126000566"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102235","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102235"}}